Abstract
Passive immunotherapy using heteroantisera for the treatment of cancer in animals and humans has been studied for over 50 years. Attempts have been made to treat animal tumors with sera from immunized syngeneic, allogeneic, or xenogeneic animals. A number of studies of passive immunotherapy using heterologous antisera in humans have also been performed [1]. These studies have generally been attempted in patients with large tumor burdens, and, as would be expected, responses have been transient at best. A wide variety of patients with leukemias and lymphomas have been treated with antisera raised in sheep, horses, rabbits, and goats. Problems such as anaphylaxis, serum sickness, and severe cytopenias have been encountered with these antisera.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Rosenberg SA, Terry WD: Passive immunotherapy of cancer in animals and man. Adv Cancer Res 25:323–388, 1977.
Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40:3147, 1980.
Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306:517, 1982.
Meeker TC, Lowder J, Maloney DG, et al: A clinical trial of anti-idiotype therapy of B cell malignancies. Blood 65:1349, 1985.
Rankin EM, Hekman A, Somers R, Huinink B: Treatment of two patients with B cell lymphoma with monoclonal anti-idiotype antibodies. Blood 65:1373, 1985.
Giardina SL, Schroff RW, Woodhouse CS, et al: The generation of monoclonal antiidiotype antibodies to human B cell-derived leukemias and lymphomas. J Immunol 135:653, 1985.
Press OW, Appelbaum F, Ledbetter JA, et al: Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. Blood 69:584, 1987.
Dillman RO, Shawler DL, Sobol RE, et al: Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 59:1036, 1982.
Foon KA, Schroff RW, Bunn RA, et al: Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 64:1085, 1984.
Dillman RO, Shawler DL, Dillman JB, Royston R: Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 2:881, 1984.
Bertram JH, Gill PS, Levine AM, et al: Monoclonal antibody T101 in T cell malignancies: A clinical, pharmacokinetic, and immunologic correlation. Blood 67:1680, 1986.
Foon KA, Schroff RW, Bunn RA: Monoclonal antibody therapy for patients with leukemia and lymphoma. In: Foon KA, Morgan AC (eds): Monoclonal Antibody Therapy of Human Cancer, Boston, Martinus Nijhoff Publishing, 101:85, 1985.
Miller RA, Oseroff AR, Stratte PT, Levy R: Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62:988, 1983.
Miller RA, Levy R: Response of cutaneous T cell lymphoma to therapy of hybridoma monoclonal antibody in a patient with T cell leukemia. Lancet 2:226, 1981.
Ritz J, Pesando JM, Sallan SE, et al: Serotherapy of acute-lymphoblastic leukemia with monoclonal antibody. Blood 58:141, 1981.
Ball ED, Bernier GM, Cornwell GG, Mclntyre OR, O’Donnell JF, Fanger MW: Monoclonal antibodies to myeloid differentiation antigens: In vivo studies of three patients with acute myelogenous leukemia. Blood 62:1203–1210, 1983.
Waldmann TA, Longo DL, Leonard WJ, et al: Interleukin 2 receptor (Tac antigen) expression in HTLV-1-associated adult T-cell leukemia. Cancer Res 45:4559s-4562s, 1985.
Jerne NK: Towards a network theory of the immune system. Ann Immunol 125C:373, 1974.
Meeker T, Lowder J, Cleary ML, et al: Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med 312:1658, 1985.
Cleary ML, Meeker TC, Levy S, et al: Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell 44:97, 1986.
Raffeld M, Neckers L, Longo DL, Cossman J: Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by anti-idiotype. N Engl J Med 312:1653, 1985.
Carroll WL, Lowder J, Streifer R, Warnke R, Levy S, and Levy R: Idiotype variant cell populations in patients with B cell lymphoma. J Exp Med 164:1566, 1986.
Lowder JN, Meeker TC, Campbell M, et al: Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: Correlation with clinial responses. Blood 69:199, 1987.
Garcia CF, Lowder J, Meeker TC, Bindl J, Levy R, Warnke RA: Differences in “host infiltrates” among lymphoma patients treated with anti-idiotype antibodies: Correlation with treatment responses. J Immunol 135:4252, 1985.
Schroff RW, Farrell MM, Klein RA, Oldham RK, Foon KA: T65 antigen modulation in phase I monoclonal antibody trial with chronic lymphocytic leukemia patients. J Immunol 133:1641, 1984.
Goldenberg DM, DeLand FH: History and status of tumor imaging with radiolabeled antibodies. J Biol Resp Modif 1:121, 1982.
Bunn PA, Carrasquillo JA, Keenan AM, et al: Successful imaging of malignant non-Hodgkin’s lymphoma using radiolabeled monoclonal antibody. Lancet 2:1219, 1984.
Carrasquillo JA, Bunn PA, Keenan AM, et al: Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labelled T101 monoclonal antibody. N Engl J Med 315:673, 1986.
Mulshine J, Keenan A, Carrasquillo J, et al: Successful immunoscintigraphy after lymphatic delivery of 111In-T101. Proc Am Soc Clin Oncol 4:205, 1985.
DeNardo SJ, DeNardo GL, O’Grady LF, et al: Radioimmunotherapy of patients with B-cell lymphomas using I131 Lym-1 MAb (abstract). J Nuc Med. 27:903, 1986.
Rosen ST, Zimmer AM, Goldman-Leikin R, et al: Radioimmunodetection and radioimmunotherapy of cutaneous T-cell lymphomas using an 131I-labeled monoclonal antibody: An Illinois Cancer Council Study. J Clin Oncol 5:562–573, 1987.
Lenhard RE, Order SE Jr, Spunberg JJ, Asbell SO, Leibel SA: Isotopic immunoglobulin: A new systemic therapy for advanced Hodgkin’s disease. J Clin Oncol 3:1296–1300, 1985.
Laurent G, Pris J, Farcet JP, et al: Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. Blood 68:752, 1986.
Hertler AA, Schlossman DM, Borowitz MJ, Frankel AE: A phase I study of T101 RTA immunotoxin in refractory chronic lymphocytic leukemia. Blood 68(suppl l):223a, 1986.
Sklar J, Cleary ML, Thielmans K, Gralow J, Warnke R, Levy R: Biclonal B-cell lymphoma. N Engl J Med 311:20, 1984.
Giardina SA, Schroff RW, Woodhouse CS, et al: Detection of two malignant B-cell clones in a single patient using anti-idiotype monoclonal antibodies and immunoglobulin gene rearrangement. Blood 66:1017, 1984.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Kluwer Academic Publishers
About this chapter
Cite this chapter
Kaminski, M.S., Foon, K.A. (1988). Monoclonal antibody therapy of lymphomas and leukemia. In: Bennett, J.M., Foon, K.A. (eds) Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias. Cancer Treatment and Research, vol 38. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1713-5_8
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1713-5_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8965-4
Online ISBN: 978-1-4613-1713-5
eBook Packages: Springer Book Archive